
    
      The purpose of this study is to assess the level of neuroinflammation in Alzheimer Disease
      subject (mild to moderate) estimated with Binding Potential (BP) of [18F]DPA-714 , and its
      relationship with the kinetics of cognitive decline over a 24-month follow-up period (as
      assessed by ADAS-Cog and MMSE scores).

      (DPA-714 :
      N,N-diethyl-2-[4-(2-fluoroethoxy)phenyl]-5,7-dimethylpyrazolo[1,5-a]pyrimidine-3-acetamide)
    
  